Table 2. Association between myeloid CH subtypes and eGFR.cys score after removing participants with prevalent myeloid neoplasms.
| Predictor | Cases | β | CI 2.5% | CI 97.5% | P |
|---|---|---|---|---|---|
| myeloid CH | 3330 | -1.05 | -1.54 | -0.57 | 8.80x10-5 |
| myeloid mCA | 148 | -3.36 | -5.65 | -1.07 | 9.11 x10-3 |
| myeloid genes | 3241 | -1.08 | -1.57 | -0.60 | 6.25 x10-5 |
| DNMT3A | 1446 | 0.14 | -0.59 | 0.87 | 0.73 |
| TET2 | 778 | -1.74 | -2.74 | -0.73 | 1.84x10-3 |
| ASXL1 | 283 | -1.59 | -3.21 | 0.03 | 0.09 |
| JAK2 | 92 | -4.69 | -7.56 | -1.82 | 3.21x10-3 |
| GNB1 | 86 | -3.51 | -6.40 | -0.62 | 0.04 |
| SRSF2 | 67 | -2.42 | -5.94 | 1.11 | 0.27 |
| TP53 | 62 | -0.01 | -3.30 | 3.29 | 1.00 |
| PPM1D | 61 | -5.87 | -9.43 | -2.31 | 3.08 x10-3 |
| SF3B1 | 52 | -2.37 | -6.27 | 1.52 | 0.32 |
| FLT3 | 36 | -0.65 | -5.49 | 4.19 | 0.81 |
| GNAS | 33 | 1.89 | -2.61 | 6.40 | 0.49 |
| NF1 | 28 | -1.03 | -6.07 | 4.01 | 0.73 |
| CBL | 28 | -12.14 | -17.40 | -6.88 | 3.44 x10-5 |
| STAG2 | 27 | 3.90 | -1.37 | 9.16 | 0.23 |
| PRPF40B | 26 | 2.96 | -2.29 | 8.21 | 0.35 |
| CREBBP | 24 | -3.10 | -8.49 | 2.30 | 0.34 |
| KDM6A | 22 | -2.68 | -8.49 | 3.14 | 0.45 |
| BRCC3 | 21 | -1.72 | -7.70 | 4.27 | 0.66 |
| IDH2 | 14 | -5.56 | -13.78 | 2.67 | 0.28 |
| KMT2D | 13 | -3.43 | -10.54 | 3.69 | 0.44 |
*
59 participants had both myeloid mutated genes and mCA